Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 20/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19633495 | 0.88 | HRH3 (0.66) | HRH3 | |
| SCHEMBL16823278 | 0.87 | HRH3 (0.52) | HRH3 | |
| SCHEMBL12030651 | 0.86 | HRH3 (0.68) | HRH3 | |
| SCHEMBL12499576 | 0.85 | HRH3 (0.66) | HRH3 | |
| SCHEMBL14423906 | 0.85 | HRH3 (0.66) | HRH3 | |
| SCHEMBL10057696 | 0.85 | HRH3 (0.66) | HRH3 | |
| SCHEMBL3309280 | 0.85 | HRH3 (0.66) | HRH3 | |
| SCHEMBL8025279 | 0.84 | HRH3 (0.69) | HRH3 | |
| SCHEMBL14609290 | 0.83 | HRH3 (0.71) | HRH3 | |
| SCHEMBL5206162 | 0.82 | HRH3 (0.67) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023217201-A2 | NOVEL PYRIMIDO-HETEROCYCLIC NOVEL COMPOUND SERVING AS WEE1 INHIBITOR AND APPLICATION THEREOF | 杭州德睿智药科技有限公司 | 2023-11-16 | — | — | WO | disclosed |
| US-8563549-B2 | Pyrimidine derivatives used as PI-3 kinase inhibitors | NOVARTIS AG (CH) | 2013-10-22 | — | — | US | disclosed |
| US-8563549-B2 | Pyrimidine derivatives used as PI-3 kinase inhibitors | NOVARTIS AG (CH) | 2013-10-22 | — | — | US | disclosed |
| US-8563549-B2 | Pyrimidine derivatives used as PI-3 kinase inhibitors | NOVARTIS AG (CH) | 2013-10-22 | — | — | US | disclosed |
| EP-2261223-B1 | Pyrimidine derivatives used as pi-3 kinase inhibitors | NOVARTIS AG (CH) | 2013-06-12 | — | — | EP | disclosed |
| US-20120225859-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-09-06 | — | — | US | disclosed |
| US-20120225859-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-09-06 | — | — | US | disclosed |
| US-20120225859-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-09-06 | — | — | US | disclosed |
| US-8217035-B2 | Pyrimidine derivatives used as PI-3-kinase inhibitors | NOVARTIS AG (CH) | 2012-07-10 | — | — | US | disclosed |
| US-8217035-B2 | Pyrimidine derivatives used as PI-3-kinase inhibitors | NOVARTIS AG (CH) | 2012-07-10 | — | — | US | disclosed |
| EP-2261223-A1 | Pyrimidine derivatives used as pi-3 kinase inhibitors | Novartis AG (CH) | 2010-12-15 | — | — | EP | disclosed |
| US-20100249126-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3-KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249126-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3-KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249126-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3-KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2010-09-30 | — | — | US | disclosed |
| EP-1984350-B1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-08-18 | — | — | EP | disclosed |
| US-20090137576-A1 | Novel Piperidine Derivative | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1984350-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | Novartis AG (CH) | 2008-10-29 | — | — | EP | disclosed |
| EP-1892241-A1 | NOVEL PIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-02-27 | — | — | EP | disclosed |
| WO-2007084786-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007084786-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137576-A1 | Novel Piperidine Derivative | HRH4, HRH3, HRH1 | HRH3 2/4885 |
| US-20100249126-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3-KINASE INHIBITORS | PIK3CA, PI4KA, PI4KB | HRH3 2621/4885 |
| US-20120225859-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | PIK3CA, PI4KA, PI4KB | HRH3 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.